<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00078325</url>
  </required_header>
  <id_info>
    <org_study_id>C10953/3021/AP/MN</org_study_id>
    <nct_id>NCT00078325</nct_id>
  </id_info>
  <brief_title>Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)</brief_title>
  <official_title>A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 and 250 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether treatment with Armodafinil
      (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness
      associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) by measuring mean sleep
      latency from the Maintenance of Wakefulness Test (MWT) (30-minute version) (average of 4 naps
      at 0900, 1100, 1300, and 1500) and by Clinical Global Impression of Change (CGI-C) ratings
      (as related to general condition) at week 12, or last post-baseline visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maintenance of Wakefulness Test (MWT)</measure>
    <time_frame>change from baseline at 12 weeks</time_frame>
    <description>The MWT is an objective assessment of sleepiness that measures the ability of a subject to remain awake. Long latencies to sleep are indicative of a patient's ability to remain awake. The primary variable was the 30 minute MWT (average of 4 naps at 0900, 1100, 1300, and 1500) assessed at the last postbaseline observation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression of Change (CGI-C)</measure>
    <time_frame>change from baseline at 12 weeks</time_frame>
    <description>The CGI-C represents a subjective measure of the patient's global health (clinician's rating of disease severity as compared with a pretreatment evaluation as assessed by the CGI-S). The CGI-C scale (change from baseline)categories include:1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; and 7=Very much worse. Severity of illness (CGI-S) was assessed at baseline includes categories: 1=Normal; 2=Borderline ill; 3=Mildly (Slightly) ill; 4=Moderately ill; 5=Markedly ill; 6=Severely ill; and 7=Among the most extremely ill patients.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">395</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Hypopnea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Armodafinil 250 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Armodafinil 150 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil 250 mg/day</intervention_name>
    <description>Armodafinil 250 mg once daily in the morning</description>
    <arm_group_label>1</arm_group_label>
    <other_name>NUVIGIL</other_name>
    <other_name>CEP-10953</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil 150 mg/day</intervention_name>
    <description>Armodafinil 150 mg once daily in the morning</description>
    <arm_group_label>2</arm_group_label>
    <other_name>NUVIGIL</other_name>
    <other_name>CEP-10953</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets once daily in the morning</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are included in the study if all of the following criteria are met:

          1. Written informed consent is obtained.

          2. The patient is an outpatient, man or woman of any ethnic origin, 18 to 65 years of age
             (inclusive).

          3. The patient has a complaint of excessive sleepiness despite nCPAP therapy being
             effective and being a regular user of nCPAP therapy.

          4. The patient has a current diagnosis of OSAHS according to International Classification
             of Sleep Disorders (ICSD) criteria.

          5. The patient meets the following nCPAP therapy requirements:

               -  Adequate education and intervention efforts to encourage nCPAP therapy use must
                  be documented.

               -  A patient's nCPAP therapy regimen must be stable for at least 4 weeks.

               -  nCPAP therapy is shown to be effective, with effectiveness defined as having an
                  apnea-hypopnea index (AHI) of 10 or less during nocturnal PSG, and, in the
                  opinion of the investigator, nCPAP is effective therapy.

               -  Following demonstration of effectiveness, evidence of regular nCPAP usage must be
                  shown during a 2-week evaluation period (ie, nCPAP usage for at least 4
                  hours/night on at least 70% of the nights).

          6. The patient is in good health as determined by a medical and psychiatric history,
             physical examination, ECG, and serum chemistry and hematology.

          7. Women must be surgically sterile, 2 years postmenopausal, or, if of child-bearing
             potential, using a medically accepted method of birth control (ie, barrier method with
             spermicide, steroidal contraceptive [oral, implanted, and Depo-Provera contraceptives
             must be used in conjunction with a barrier method], or intrauterine device [IUD]) and
             agree to continued use of this method for the duration of the study.

          8. The patient has a Clinical Global Impression of Severity of Illness (CGI-S) rating of
             4 or more.

          9. The patient has an ESS score of 10 or more.

         10. The patient does not have any medical or psychiatric disorders that could account for
             the excessive sleepiness.

         11. The patient is able to complete self rating scales and computer-based testing.

         12. The patient is willing and able to comply with study restrictions and to attend
             regularly scheduled clinic visits as specified in this protocol.

        Exclusion Criteria:

        Patients are excluded from participating in this study if 1 or more of the following
        criteria are met:

          1. has any clinically significant, uncontrolled medical or psychiatric conditions
             (treated or untreated)

          2. has a probable diagnosis of a current sleep disorder other than OSAHS

          3. consumes caffeine including coffee, tea and/or other caffeine containing beverages or
             food averaging more than 600 mg of caffeine per day

          4. used any prescription drugs disallowed by the protocol or clinically significant use
             of over the-counter (OTC) drugs within 7 days before the second screening visit

          5. has a history of alcohol, narcotic, or any other drug abuse as defined by the
             Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric
             Association, 4th Edition (DSM IV)

          6. has a positive urine drug screen (UDS)

          7. has a clinically significant deviation from normal in the physical examination

          8. is a pregnant or lactating woman. (Any woman becoming pregnant during the study will
             be withdrawn from the study.)

          9. has used an investigational drug within 1 month before the initial screening visit

         10. has any disorder that may interfere with drug absorption, distribution, metabolism, or
             excretion (including gastrointestinal surgery)

         11. has a known clinically significant drug sensitivity to stimulants or modafinil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2004</study_first_submitted>
  <study_first_submitted_qc>February 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2004</study_first_posted>
  <results_first_submitted>June 1, 2009</results_first_submitted>
  <results_first_submitted_qc>July 6, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2010</results_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2013</last_update_posted>
  <keyword>Excessive Sleepiness</keyword>
  <keyword>Obstructive Sleep Apnea</keyword>
  <keyword>Obstructive Sleep Hypopnea</keyword>
  <keyword>nCPAP</keyword>
  <keyword>Cephalon</keyword>
  <keyword>Cephalon, Inc</keyword>
  <keyword>NUVIGIL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>37 centers in the US and Canada. First patient enrolled: 19 February 2004/ Last patient last visit: 6 November 2004</recruitment_details>
      <pre_assignment_details>3 female patients withdrew after randomization but prior to receiving study drug (1 had a protocol violation and 2 were lost to follow-up)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Armodafinil 250 mg/Day</title>
          <description>Armodafinil 250 mg once daily in the morning</description>
        </group>
        <group group_id="P2">
          <title>Armodafinil 150 mg/Day</title>
          <description>Armodafinil 150 mg once daily in the morning</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching placebo tablets once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Armodafinil 250 mg/Day</title>
          <description>Armodafinil 250 mg once daily in the morning</description>
        </group>
        <group group_id="B2">
          <title>Armodafinil 150 mg/Day</title>
          <description>Armodafinil 150 mg once daily in the morning</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching placebo tablets once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="131"/>
            <count group_id="B2" value="131"/>
            <count group_id="B3" value="130"/>
            <count group_id="B4" value="392"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>3 female patients withdrew after randomization but prior to receiving study drug (1 had a protocol violation and 2 were lost to follow-up)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.1" spread="8.74"/>
                    <measurement group_id="B2" value="49.3" spread="9.17"/>
                    <measurement group_id="B3" value="50.1" spread="9.43"/>
                    <measurement group_id="B4" value="49.5" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>3 female patients withdrew after randomization but prior to receiving study drug (1 had a protocol violation and 2 were lost to follow-up)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maintenance of Wakefulness Test (MWT)</title>
        <description>The MWT is an objective assessment of sleepiness that measures the ability of a subject to remain awake. Long latencies to sleep are indicative of a patient’s ability to remain awake. The primary variable was the 30 minute MWT (average of 4 naps at 0900, 1100, 1300, and 1500) assessed at the last postbaseline observation.</description>
        <time_frame>change from baseline at 12 weeks</time_frame>
        <population>Safety Analysis set of 392 total patients: 3 patients withdrew after randomization but prior to receiving study drug (1 had a protocol violation and 2 were lost to follow-up)
Full Analysis set of 365 total patients: 27 patients that had withdrawn from the study were non-evaluable for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil 250 mg/Day</title>
            <description>Armodafinil 250 mg once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Armodafinil 150 mg/Day</title>
            <description>Armodafinil 150 mg once daily in the morning</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance of Wakefulness Test (MWT)</title>
          <description>The MWT is an objective assessment of sleepiness that measures the ability of a subject to remain awake. Long latencies to sleep are indicative of a patient’s ability to remain awake. The primary variable was the 30 minute MWT (average of 4 naps at 0900, 1100, 1300, and 1500) assessed at the last postbaseline observation.</description>
          <population>Safety Analysis set of 392 total patients: 3 patients withdrew after randomization but prior to receiving study drug (1 had a protocol violation and 2 were lost to follow-up)
Full Analysis set of 365 total patients: 27 patients that had withdrawn from the study were non-evaluable for efficacy.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="8.07"/>
                    <measurement group_id="O2" value="1.7" spread="6.49"/>
                    <measurement group_id="O3" value="-1.7" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Treatment and country as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANOVA</method>
            <method_desc>Treatment and country as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Impression of Change (CGI-C)</title>
        <description>The CGI-C represents a subjective measure of the patient’s global health (clinician’s rating of disease severity as compared with a pretreatment evaluation as assessed by the CGI-S). The CGI-C scale (change from baseline)categories include:1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; and 7=Very much worse. Severity of illness (CGI-S) was assessed at baseline includes categories: 1=Normal; 2=Borderline ill; 3=Mildly (Slightly) ill; 4=Moderately ill; 5=Markedly ill; 6=Severely ill; and 7=Among the most extremely ill patients.</description>
        <time_frame>change from baseline at 12 weeks</time_frame>
        <population>Safety Analysis set of 392 total patients (ITT): 3 patients withdrew after randomization but prior to receiving study drug (1 had a protocol violation and 2 were lost to follow-up)</population>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil 250 mg/Day</title>
            <description>Armodafinil 250 mg once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Armodafinil 150 mg/Day</title>
            <description>Armodafinil 150 mg once daily in the morning</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Change (CGI-C)</title>
          <description>The CGI-C represents a subjective measure of the patient’s global health (clinician’s rating of disease severity as compared with a pretreatment evaluation as assessed by the CGI-S). The CGI-C scale (change from baseline)categories include:1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; and 7=Very much worse. Severity of illness (CGI-S) was assessed at baseline includes categories: 1=Normal; 2=Borderline ill; 3=Mildly (Slightly) ill; 4=Moderately ill; 5=Markedly ill; 6=Severely ill; and 7=Among the most extremely ill patients.</description>
          <population>Safety Analysis set of 392 total patients (ITT): 3 patients withdrew after randomization but prior to receiving study drug (1 had a protocol violation and 2 were lost to follow-up)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for country.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for country.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Armodafinil 250 mg/Day</title>
          <description>Armodafinil 250 mg once daily in the morning</description>
        </group>
        <group group_id="E2">
          <title>Armodafinil 150 mg/Day</title>
          <description>Armodafinil 150 mg once daily in the morning</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching placebo tablets once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sponsor's Medical Director, Clinical Research</name_or_title>
      <organization>Cephalon</organization>
      <phone>1-877-237-4879</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

